Anders Muszta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anders Muszta has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anders Bergström
Västra Götalandsregionen, Department of Clinical Pathology, Sahlgrenska University Hospital, SE41335 Gothenburg, Sweden
1 shared publication - Anne Huibers
Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, P.O. Box 400, SE40530 Gothenburg, Sweden
1 shared publication - Axel Nelson
Västra Götalandsregionen, Department of Oncology, Sahlgrenska University Hospital, SE41335 Gothenburg, Sweden
1 shared publication - Emel Cicek
Västra Götalandsregionen, Department of Clinical Pathology, Södra Älvsborgs Sjukhus, SE50182 Borås, Sweden
1 shared publication - Iva Johansson
Department of Clinical Pathology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden
1 shared publication - Jonas Selling
Statistikakademin AB, SE75321 Uppsala, Sweden
1 shared publication
Latest Publications
- Open Access
Selecting Representative Tumour Bed Slices May Allow Reduced Embedding Without Loss of Accuracy in Response Evaluation to Neoadjuvant Immunotherapy in Stage IIIB/C Cutaneous Melanoma
Background/Objectives: Histological assessment of the response to neoadjuvant immunotherapy in stage IIIB/C cutaneous melanoma is commonly performed using the INMC recommendations, which advocate embedding the entire tumour bed. However, this approach is highly resource-intensive. The original Swedish National Clinical Cancer Care Guidelines for Melanoma recommend a reduced embedding strategy, but its diagnostic performance in comparison with full embedding has not been systematically evaluated. We aimed to assess whether a reduced sampling approach based on selecting representative tumour bed slices provides comparable response classification to comprehensive embedding according to the INMC protocol. Methods: Ten consecutive patients with stage IIIB/C melanoma treated with neoadjuvant immunotherapy and subsequent lymph node dissection were included. All lymph node material was completely embedded, and the pathological response was evaluated using INMC criteria. Response classification based on the full embedding of the tumour bed was compared with reduced-sampling approaches that simulate the Swedish National Clinical Cancer Care Guidelines for Melanoma. Agreement between sampling methods was analyzed. Results: Targeted reduced sampling of two slices per lymph node demonstrated complete agreement with the full embedding for the INMC response category. Conclusions: In our study, a targeted reduced-embedding strategy focusing on slices with the largest area of tumour bed enables accurate histological assessment of response to neoadjuvant immunotherapy in stage IIIB/C melanoma while substantially reducing workload. These findings support the feasibility of targeted reduced embedding of instructions in the Swedish National Clinical Cancer Care Guidelines for Melanoma as an efficient alternative to full embedding of the lymphadenectomy specimens.
Open AccessSelecting Representative Tumour Bed Slices May Allow Reduced Embedding Without Loss of Accuracy in Response Evaluation to Neoadjuvant Immunotherapy in Stage IIIB/C Cutaneous Melanoma
Background/Objectives: Histological assessment of the response to neoadjuvant immunotherapy in stage IIIB/C cutaneous melanoma is commonly performed using the INMC recommendations, which advocate embedding the entire tumour bed. However, this approach is highly resource-intensive. The original Swedish National Clinical Cancer Care Guidelines for Melanoma recommend a reduced embedding strategy, but its diagnostic performance in comparison with full embedding has not been systematically evaluated. We aimed to assess whether a reduced sampling approach based on selecting representative tumour bed slices provides comparable response classification to comprehensive embedding according to the INMC protocol. Methods: Ten consecutive patients with stage IIIB/C melanoma treated with neoadjuvant immunotherapy and subsequent lymph node dissection were included. All lymph node material was completely embedded, and the pathological response was evaluated using INMC criteria. Response classification based on the full embedding of the tumour bed was compared with reduced-sampling approaches that simulate the Swedish National Clinical Cancer Care Guidelines for Melanoma. Agreement between sampling methods was analyzed. Results: Targeted reduced sampling of two slices per lymph node demonstrated complete agreement with the full embedding for the INMC response category. Conclusions: In our study, a targeted reduced-embedding strategy focusing on slices with the largest area of tumour bed enables accurate histological assessment of response to neoadjuvant immunotherapy in stage IIIB/C melanoma while substantially reducing workload. These findings support the feasibility of targeted reduced embedding of instructions in the Swedish National Clinical Cancer Care Guidelines for Melanoma as an efficient alternative to full embedding of the lymphadenectomy specimens.